[Skip to Content]
[Skip to Content Landing]
Article
November 13, 1967

Physicochemical and Biochemical Aspects of Pharmacology

Author Affiliations

From the Laboratory of Chemical Pharmacology, National Heart Institute, National Institutes of Health, Bethesda, Md.

JAMA. 1967;202(7):600-609. doi:10.1001/jama.1967.03130200086016
Abstract

There are two facets to the problem of the biochemical and physical aspects of drug actions, the influence of drugs on the body and the influence of the body on drugs. In the past, pharmacology has emphasized the action of drugs on the living organism. But to be effective, a substance must have characteristics that allow it to reach its site of action in adequate concentration and to remain there for a suitable period of time. For this reason, we become concerned with the physical and biochemical factors that determine the duration of drug action.

About 25 years ago, when I first became interested in the fate of drugs, I felt like the bat in Aesop's fable. Journals of pharmacology showed considerable reluctance in associating themselves with this "biochemical" topic, while biochemical journals refused these "drug" papers outright. But over the years pharmacology has broadened and these sort of studies

References
1.
Overton, E.:  Beitrage zur Allgemeinen Muskel-und Nerven-physiologie ,  Pflueger Arch Ges Physiol 92:115-280. 1902.Crossref
2.
Collander, R., and Barlund, H.:  Permeabilitätsstudien an Chara Ceratophylla: II. Die Permeabilität für Nichelektrolyte ,  Acta Bot Fenn 11:1-114, 1933.
3.
Shore, P.A.; Brodie. B.B.; and Hogben, C.A.M.:  The Gastric Secretion of Drugs: A pH Partition Hypothesis ,  J Pharmacol Exp Ther 119:361-369 ( (March) ) 1957.
4.
Schanker. L.S., et al:  Absorption of Drugs From the Stomach: I. The Rat ,  J Pharmacol Exp Ther 120:528-539 ( (Aug) ) 1957.
5.
Hogben, C.A.M., et al:  On the Mechanism of Intestinal Absorption of Drugs .  J Pharmacol Exp Ther 125:275-282 ( (April) ) 1959.
6.
Mayer. S.; Maickel, R.P.; and Brodie, B.B.:  Kinetics of Penetration of Drugs and Other Foreign Compounds Into Cerebrospinal Fluid and Brain ,  J Pharmacol Exp Ther 127:205-211 ( (Nov) ) 1959.
7.
Brodie, B.B.; Kurz, H.; and Schanker. L.S.:  The Importance of Dissociation Constants and Lipid Solubility in Influencing the Passage of Drugs Into the Cerebrospinal Fluid ,  J Pharmacol Exp Ther 130:20-25 ( (Sept) ) 1960.
8.
Brodie, B.B., et al:  The Fate of Thiopental in Man and a Method for its Estimation in Biological Material .  J Pharmacol Exp Ther 98:85-96 ( (Jan) ) 1950.
9.
Burns, J.J., et al:  The Physiological Disposition of Phenylbutazone (Butazolidin) in Man and a Method for its Estimation in Biological Material ,  J Pharmacol Exp Ther 109:346-357 ( (Nov) ) 1953.
10.
Shannon, J.A., et al:  The Pharmacological Basis for the Rational Use of Atabrine in the Treatment of Malaria ,  J Pharmacol Exp Ther 81:307-330 ( (Aug) ) 1944.
11.
Shannon, J.A.:  The Study of Antimalarials and Antimalarial Activity in the Human Malarias ,  Harvey Lect , series 41, 1945-1946, pp 43-89.
12.
Tréfouël, J., et al:  Activité du p-aminophénylsulfamide sur les infections streptococciques expérimentales de la souris et du lapin ,  C R Soc Biol 120:756-758, 1935.
13.
Brodie, B.B., and Axelrod, J.:  The Fate of Acetanilide in Man ,  J Pharmacol Exp Ther 94:29-38 ( (Sept) ) 1948.
14.
Brodie, B.B., and Axelrod, J.:  The Fate of Phenacetin in Man ,  J Pharmacol Exp Ther 97:58-67 ( (Sept) ) 1949.
15.
Burns, J.J., et al:  The Metabolic Fate of Phenylbutazone (Butazolidin) in Man ,  Pharmacol Exp Ther 113:481-489 ( (April) ) 1955.
16.
Yü, T.F., et al:  Phenylbutazone Metabolites: Antirheumatic, Sodium-Retaining and Uricosuric Effects in Man ,  J Pharmacol Exp Ther 123:63-69 ( (May) ) 1958.
17.
Burns, J.J. et al:  A Potent New Uricosuric Agent, the Sulfoxide Metabolite of the Phenylbutazone Analogue, G-25671 ,  J Pharmacol Exp Ther 119:418-426 ( (March) ) 1957.
18.
Brodie, B.B.; Lief, P.A.; and Poet, R.:  The Fate of Procaine in Man Following its Intravenous Administration and Methods for the Estimation of Procaine and Diethylaminoethanol ,  J Pharmacol Exp Ther 94:359-366 ( (Dec) ) 1948.
19.
Mark, L.C., et al:  The Physiological Disposition and Cardiac Effects of Procaine Amide ,  J Pharmacol Exp Ther 102:5-15 ( (May) ) 1951.
20.
Conney, A.H., and Burns, J.J.:  Biochemical Pharmacological Considerations of Zoxazolamine and Chlorzoxazone Metabolism ,  Ann NY Acad Sci 86:167-177 ( (March 30) ) 1960.Crossref
21.
Gillette, J.R., et al:  Isolation From Rat Brain of a Metabolic Product, Desmethylimipramine, That Mediates the Antidepressant Activity of Imipramine (Tofranil) ,  Experientia 17:417-418 ( (Sept 15) ) 1961.Crossref
22.
Brodie, B.B.; Gillette, J.R.; and La Du, B.N.:  Enzymatic Metabolism of Drugs and Other Foreign Compounds ,  Ann Rev Biochem 27:427-454, 1958.Crossref
23.
Jondorf, W.R.; Maickel, R.P.; and Brodie, B.B.:  Inability of Newborn Mice and Guinea Pigs to Metabolize Drugs ,  Biochem Pharmacol 1:352-354 ( (March) ) 1958.Crossref
24.
Fouts, J.R., and Adamson, R.H.:  Drug Metabolism in the Newborn Rabbit ,  Science 129:897-898 ( (April 3) ) 1959.Crossref
25.
Gillette, J.R.:  Biochemistry of Drug Oxidation and Reduction by Enzymes in Hepatic Endoplasmic Reticulum ,  Advances Pharmacol 4:219-261, 1966.
26.
Remmer, H., et al:  Drug Interaction With Hepatic Microsomal Cytochrome ,  Molec Pharmacol 2:187-190 ( (March) ) 1966.
27.
Davies, D.; Gigon, P.; and Gillette, J.R.:  Species Differences in Ethylmorphine Demethylation, the Amount of P-450 and Ethylmorphine-Induced Spectral Changes in Liver Microsomes ,  Pharmacologist 9:203, 1967.
28.
Weiner, M., et al:  Drug Interactions: The Effect of Combined Administration on the Half-Life of Coumarin and Pyrazolone Drugs in Man ,  Fed Proc 24:153 ( (March) -April) 1965.
29.
Sjöqvist, F.:  Psychotropic Drugs (2): Interaction Between Monoamine Oxidase (MAO) Inhibitors and Other Substances ,  Proc Roy Soc Med 58:967-978 ( (Nov) ) 1965.
30.
Burns, J.J., and Conney, A.H.:  Enzyme Stimulation and Inhibition in the Metabolism of Drugs ,  Proc Roy Soc Med 58:955-960 ( (Nov) ) 1965.
31.
Hammer, W.; Ideström, C.M.; and Sjöqvist, F.: " Chemical Control of Antidepressant Therapy ," in Garattini, S., and Dukes, M.N.G. (eds.):  Proceedings of International Symposium on Antidepressant Drugs , Amsterdam: Excerpta Medica Foundation, 1967, pp 301-310.
32.
Bums, J.J., et al:  The Physiological Disposition and Fate of Meperidine (Demerol) in Man and a Method for its Estimation in Plasma ,  J Pharmacol Exp Ther 114:289-298 ( (July) ) 1955.
33.
Burns, J.J., et al:  The Biotransformation of Ethyl Biscoumacetate (Tromexan) in Man, Rabbit and Dog ,  J Pharmacol Exp Ther 108:33-41 ( (May) ) 1953.
34.
Quinn, G.P.; Axelrod, J.; and Brodie. B.B.:  Species, Strain and Sex Differences in Metabolism of Hexobarbitone, Amidopyrine, Antipyrine and Aniline .  Biochem Pharmacol 1:152-159 ( (Oct) ) 1958.Crossref
35.
Brodie, B.B., et al:  Series of Papers on Methods ,  J Biol Chem 168:299-344 ( (April) ) 1947.
36.
Hammer, W.M.. and Brodie, B.B.:  Application of Isotope Derivative Technique to Assay of Secondary Amines: Estimation of Desipramine by Acetylation with 3H-Acetic Anhydride ,  J Pharmacol Exp Ther , to be published.
37.
Curry, S.H., and Brodie, B.B.:  Estimation of Nanogram Quantities of Chlorpromazine in Plasma Using Gas-Liquid Chromatography, With an Electron-Capture Detector ,  Fed Proc 26:761 ( (March) -April) 1967.
38.
Freireich, E.J., et al:  Quantitative Comparison of Toxicity of Anticancer Agents in Mouse. Rat, Hamster, Dog. Monkey and Man ,  Cancer Chemother Rep 50:219-226 ( (May) ) 1966.
39.
Spector, W.S. (ed.):  Handbook of Biological Data , Philadelphia: W.B. Saunders Co., 1956, p 371.
40.
Nador, K.:  Ganglienblocker ,  Fortschr Artzneimittelforschung 2:298-416, 1960.
41.
Berliner, R.W.: " Evaluation of New Drug Affecting the Kidney ," in Zaimis, E. (ed.):  Proceedings of the Second International Pharmacological Meeting , Oxford, England: Pergamon Press. Inc., 1965, vol 8, pp 123-128.
42.
Gillette, J.R.:  Drug Toxicity as a Result of Interference With Physiological Control Mechanisms ,  Ann NY Acad Sci 123: 42-54 ( (March 12) ) 1965.Crossref
43.
Yourish, N., et al:  Effect of Phenylbutazone (Butazolidin) on Experimentally Induced Ocular Inflammation ,  Arch Ophthal 53:264-266 ( (Feb) ) 1955.Crossref
44.
Burns, J.J.: " Species Differences and Individual Variation in Drug Metabolism ," in Brodie, B.B. and Erdös, E.G. (eds.):  Proceedings of the First International Pharmacological Meeting , Oxford, England: Pergamon Press, Inc.. 1962, vol 6, pp 277-288.
45.
Sulser, F.; Bickel, M.H.; and Brodie, B.B.:  The Action of Desmethylimipramine in Counteracting Sedation and Cholinergic Effects of Reserpine-Like Drugs .  J Pharmacol Exp Ther 144:321-330 ( (June) ) 1964.
46.
Gsell, O., and Müller, W.:  Parenterale Pyramidon-Pyrazolidin-Therapie von Rheumatismus und Infekten mittels Irgrapyrin ,  Schweiz Med Wschr 80:310-316 ( (March 25) ) 1950.
47.
Brodie, B.B.: " Some Ideas on the Mode of Action of Imipramine-Type Antidepressants ," in Marks, J., and Pare, C.M. (eds.):  The Scientific Basis of Drug Therapy in Psychiatry , New York: Pergamon Press, Inc., 1965, pp 127-146.
48.
Dingell, J.V.; Sulser. F.; and Gillette, J.R.:  Species Differences in the Metabolism of Imipramine and Desmethylimipramine (DMI) ,  J Pharmacol Exp Ther 143:14-22 ( (Jan) ) 1964.
49.
Weiner, M., et al:  The Physiological Disposition of Dicumarol in Man ,  J Pharmacol Exp Ther 99:409-420 ( (Aug) ) 1950.
×